Open an account

Climb Bio

CLYM · NASDAQ

$10.80+$1.07 (+11.00%)TodayMarket closed ·
Prev close $9.73

About CLYM

Climb Bio, Inc. operates as a clinical-stage biotechnology company. The company is headquartered in Wellesley Hills, Massachusetts and currently employs 28 full-time employees. The company went IPO on 2021-08-10. The firm is focused on developing therapeutics for patients with immune-mediated diseases. The Company’s lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody designed to deplete CD19-positive B cells, including antibody-secreting cells, in order to directly reduce pathogenic autoantibodies. The reduction of autoantibodies has the potential to be disease-modifying in autoantibody-driven diseases, such as systemic lupus erythematosus, immune thrombocytopenia, and membranous nephropathy. The budoprutug is in a Phase Ib/IIa clinical trial. The firm is also developing CLYM116, an anti-APRIL antibody, in investigational new drug applications (IND)-enabling studies for IgA nephropathy (IgAN).

Employees
28
Headquarters
Wellesley Hills, Massachusetts
Listed
Aug 10, 2021
Sector
Health Care
Industry
Biotechnology
Website
climbbio.com

CLYM key statistics

Market cap
620.31M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.15M
Volume
1.37M
Open price
$9.84
High today
$10.99
Low today
$9.84
52 Week high
$18.33
52 Week low
$1.64

Climb Bio (CLYM) at a glance

Climb Bio (CLYM) last traded at $10.80, with a market cap of 620.31M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $9.84 and $10.99. The current price is 9.8% above the day's low and 1.7% below its high.

Volume so far is 1.37M shares, in line with the average of 1.15M shares a day.

Over the past year Climb Bio has ranged from $1.64 to $18.33, and now sits 55% of the way up that range.

Climb Bio met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.18 per share against an estimate of -$0.2178.

The average analyst price target is $28.41, 163.1% above the current price, from 14 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

100%of 14 analyst ratings say Buy
  • Buy100.0%
  • Hold0.0%
  • Sell0.0%
Price target · 16 analystsAvg $28.41
Low
$18.18
Now
$10.80
High
$42.00

CLYM earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 18.4% on average.

  1. Q1 FY23: reported -$0.25 per share against an estimate of -$0.255
  2. Q4 FY24: reported -$0.13 per share against an estimate of -$0.153
  3. Q1 FY25: reported -$0.31 per share against an estimate of -$0.153
  4. Q2 FY25: reported -$0.13 per share against an estimate of -$0.1887
  5. Q3 FY25: reported -$0.19 per share against an estimate of -$0.1496
  6. Q4 FY25: reported -$0.26 per share against an estimate of -$0.2009
  7. Q1 FY26: reported -$0.20 per share against an estimate of -$0.272
  8. Q2 FY26: reported -$0.18 per share against an estimate of -$0.2178

CLYM news

  • Vandana Singh

    Climb Bio’s Kidney Disease Therapy Gets Support for Extended Dosing Schedule

  • Press releaseGlobe Newswire

    Climb Bio Announces CLYM116 Phase 1 Data Demonstrating Prolonged Half-Life and Best-In-Class APRIL Suppression Supporting Every-12-Week Dosing in IgA Nephropathy

  • Vandana Singh

    Why Is Climb Bio Stock Gaining Friday?

  • Press releaseGlobe Newswire

    Climb Bio Hosts Budoprutug R&D Spotlight Event Highlighting Topline Subcutaneous Formulation Data, Broad B-Cell Mediated Disease Opportunity, and Upcoming Data Readouts

  • Press releaseGlobe Newswire

    Climb Bio to Host R&D Spotlight Webcast Highlighting Budoprutug and the CD19 Opportunity on May 5, 2026

  • Vandana Singh

    Small-Cap Biotech Climb Bio's Lead Drug Candidate Has Larger Long-Term Opportunity

  • Press releaseGlobe Newswire

    Climb Bio to Host Webcast Highlighting CLYM116 and the IgA Nephropathy (IgAN) Opportunity on September 29, 2025

  • Press releaseGlobe Newswire

    UPDATE – Climb Bio to Present at Upcoming September 2025 Investor Conferences

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.